🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Enhabit Inc EHAB R2K

Healthcare · Medical Care Facilities · United States
https://www.ehab.com

Enhabit, Inc. provides home health and hospice services in the United States. The Home Health segment offers nursing care; physical, occupational, and speech therapy; medical and social work; and home health aide services. This segment also provides patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care, and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery or injury, and respiratory diseases; and counseling for patients and their families regarding financial, personal, and social concerns that arise from a patient's health-related problems. Its Hospice segment offers nursing care; pain and symptom management; palliative and dietary counseling; social worker visits; spiritual counseling; and family member bereavement counseling to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was founded in 1998 and is headquartered in Dallas, Texas.

READ MORE ›
$13.80
+31.43% 1Y

Market & Price

Market Cap
$706.91M
Current Price
$13.80
High / Low (52W)
$14.09 / $6.52
Beta
0.96

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
20.87
PEG Ratio
-
Book Value
$10.53
Price to Book
1.31
P/S
0.66
EV/EBITDA
14.54
Dividend Yield
-

Profitability & Returns

ROCE
3.40%
ROE
-0.19%
ROA
3.08%
Profit Margin
-0.30%
Op Margin
4.38%
EPS (Latest Qtr)
$0.37
EPS (TTM)
$-0.07

Balance Sheet & Liquidity

Debt/Equity
0.82
Quick Ratio
1.46
Current Ratio
1.56
Debt
$480.10M
Total Assets
$1.17B
Current Assets
$205.60M
Working Capital
$79.30M

Ownership

Promoter Holding
3.66%
Chg in Prom Hold
-
FII / Inst Holding
100.64%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$1.17B
Total Revenue (TTM)
$1.06B
EBITDA
$80.30M
Free Cash Flow
$47.84M
Operating Cash Flow
$88.00M
Shares Outstanding
51.23M
Gross Margin
48.90%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
-0.35%
Profit 5Y
29.54%
Revenue (YoY)
1.90%
Earnings (YoY)
2.90%

PROS

  • Profit CAGR of 29.5% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -0.3% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 EHAB Enhabit Inc R2K 13.80 - $706.91M - 3.40% -0.19% -0.35% 29.54%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 286.10M273.90M274.30M268.00M265.70M265.10M262.30M258.30M262.40M260.60M--259.90M266.10M263.60M270.40M264.80M
Cost of Revenue ------------130.20M135.50M135.80M138.70M134.20M
Gross Profit 156.50M142.70M-137.70M133.40M-------129.70M130.60M127.80M131.70M130.60M
Operating Expenses ------------113.80M113.90M111.00M117.30M101.30M
Operating Income 41.40M29.10M35.40M27.30M17.90M14.20M-74.50M7.80M12.90M11.20M--15.90M16.70M16.80M14.40M29.30M
EBITDA ------------41.50M22.40M22.20M-28.20M37.60M
Interest Expense ------------9.40M8.70M8.30M7.60M10.00M
Pretax Income ------------25.80M8.00M8.40M-40.80M23.00M
Tax Provision ------------7.40M2.30M-3.20M-2.50M3.10M
Net Income 32.30M21.60M26.10M20.10M8.60M2.70M-74.40M-2.40M200.00K-200.00K--17.80M5.20M11.10M-38.70M19.20M
Diluted EPS 0.650.440.530.410.170.05-1.49-0.050.010.00--0.350.100.22-0.760.37

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 1.08B-1.07B1.05B1.03B1.06B
Cost of Revenue --525.60M535.60M530.80M540.20M
Gross Profit --545.50M510.70M504.00M519.80M
Operating Expenses --447.90M472.50M457.40M456.00M
Operating Income 102.70M-97.60M38.20M46.60M63.80M
EBITDA --22.50M-16.50M-83.60M57.90M
Interest Expense --15.00M43.00M42.90M34.00M
Pretax Income ---25.50M-90.40M-158.00M1.40M
Tax Provision --12.80M-11.40M-4.00M4.00M
Net Income 75.00M--40.40M-80.50M-156.20M-4.60M
Diluted EPS 1.512.231.26-1.61-3.11-

Compounded Sales Growth

5 Years:-0.35%
1 Year:1.90%

Compounded Profit Growth

5 Years:29.54%
1 Year:2.90%

Stock Price Performance

1 Year:+31.43%
6 Months:+72.72%
3 Months:+22.99%
1 Month:+0.66%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets ---1.53B1.43B1.23B1.17B
Current Assets ---211.80M210.10M192.70M205.60M
Cash & Equivalents ---22.90M27.40M28.40M43.60M
Inventory -------
Receivables ---149.60M164.70M149.20M144.00M
Total Liabilities ---751.50M731.90M672.10M603.00M
Current Liabilities ---132.90M137.70M126.20M126.30M
Long Term Debt ---560.00M530.10M492.60M426.00M
Total Debt ---625.20M610.10M569.50M500.00M
Total Equity 658.50M1.39B-741.70M669.70M523.50M534.00M
Shares Outstanding ---50.10M50.17M50.59M51.20M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 24.90M-80.10M48.40M51.20M70.70M
Investing Cash Flow -3.00M--42.30M-5.30M-2.40M16.70M
Financing Cash Flow -16.70M--18.60M-40.50M-48.30M-72.20M
Capital Expenditure -3.20M--7.10M-3.50M-3.80M-4.90M
Free Cash Flow 21.70M-73.00M44.90M47.40M65.80M
Net Change in Cash --19.20M2.60M500.00K15.20M

Ratios (Annual)

Figures in %.

Metric Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % --50.9%48.8%48.7%49.0%
Operating Margin % 9.5%-9.1%3.7%4.5%6.0%
Net Margin % 7.0%--3.8%-7.7%-15.1%-0.4%
ROE % 5.4%--5.4%-12.0%-29.8%-0.9%
ROCE % --7.0%2.9%4.2%6.1%

Shareholding Pattern

Insiders
3.66%
Institutions
100.64%
Public Float
104.47%

Top Institutional Holders

#Holder% HeldSharesValue
1 8 Knots Management, LLC 9.93% 5.08M $70.17M
2 Deerfield Management Company, L.P 9.27% 4.75M $65.52M
3 Blackrock Inc. 7.54% 3.86M $53.32M
4 Arex Capital Management, Lp 4.87% 2.49M $34.42M
5 Vanguard Capital Management LLC 4.17% 2.14M $29.50M
6 UBS Group AG 4.12% 2.11M $29.10M
7 Jana Partners Management, Lp 4.08% 2.09M $28.85M
8 Paradice Investment Management, LLC 3.21% 1.64M $22.69M
9 Dimensional Fund Advisors LP 2.91% 1.49M $20.59M
10 Geode Capital Management, LLC 2.32% 1.19M $16.39M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for EHAB

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks